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Novelty and Impact 
Few studies have addressed the association between genetic variability in candidate 
genes and the evolution (progression, stability or regression) of gastric cancer 
precursor lesions (GCPLs).  By using multinomial logistic regression analysis in an 
independent, long-term follow-up study, we validate previous results of the 
association between MUC2 variants and the evolution of GCPLs, and identify novel 
significant associations with variants in NFKB1 and CD14, two genes of the H. 
pylori pathway first analyzed in relation to CGPLs. 
Precursor lesions play a central role in the development of gastric cancer, yet few studies have 
examined associations between candidate gene variants and the evolution of gastric cancer 
precursor lesions (GCPLs). Here, using multinomial logistic regression analysis in a long-term 
trial of GCPL patients, the authors show that genetic variants in MUC2 are inversely associated 
with GCPL regression. Variations in NFKB1 and CD14, genes involved in the immune response 
against Helicobacter pylori infection, a cause of gastric cancer, were also associated with 
















Gastric carcinogenesis proceeds through a series of gastric cancer precursor lesions 
(GCPLs) leading to gastric cancer (GC) development. Although Helicobacter pylori 
infection initiates this process, genetic factors also play a role. We previously reported 
that genetic variability in MUC2 is associated with the evolution of GCPLs. In order to 
replicate previous results in an independent sample series and to explore whether 
genetic variability in other candidate genes plays a role in the evolution of GCPL, 
genomic DNA from 559 patients with GCPLs, recruited from 9 Spanish hospitals and 
followed for a mean of 12 years, was genotyped for 141 SNPs in 29 genes. After follow-
up, 45.5% of the lesions remained stable, 37% regressed and 17.5% progressed to a 
more severe lesion. Genetic association with the evolution of the lesions (progression 
or regression) was analyzed by multinomial and binomial logistic regression.  After 
correction for multiple comparisons, the results obtained confirmed the inverse 
association between MUC2 variants and the regression of the lesions. A significant 
association was also observed between NFKB1 and CD14 variants and the evolution of 
the lesions; interestingly, this association was with both progression and regression in 
the same direction, which could reflect the dual role of inflammation in cancer. 
Stratified analyses according to H. pylori virulence factors indicated some significant 
and differential effects but none of them passed the FDR test. These results confirm 
that genetic variability in MUC2, NFKB1 and CD14 may have a role in the evolution of 
















Gastric cancer (GC) is the fifth cause of cancer related death worldwide, its relative 
survival at 5 years is only 23% in Europe 1. GC is the outcome of a multistep sequence 
(Correa´s cascade) of GCPLs starting as a non-atrophic inflammation, which may 
progress to chronic atrophic gastritis (CAG), complete and incomplete intestinal 
metaplasia (IM), dysplasia and finally GC 2. Infection by H. pylori is the main initiating 
factor for this process; however only 1 to 4% of infected people will develop GC 3. This 
fact suggests that other factors, among which host genetic susceptibility, could 
influence the evolution (progression to a more advanced lesion or regression to a less 
severe one) of GCPLs over time.  
To our knowledge, only four studies 4–7 have evaluated the genetic association 
between SNPs in candidate genes and the evolution of GCPLs along time. In one of 
them, performed in a Spanish population from the province of Soria, our group found a 
significant association between MUC2 genetic variability and the evolution of GCPLs 4, 
which at that moment could not be replicated in an independent population. Apart 
from MUC2, in that previous study we also found a weak association between variants 
in CD14, NFKB1, CDH1, TFF1, TFF2 and IL1A genes and the evolution of GCPLs 
(unpublished results). The other studies explored the association with genes involved 
in the DNA repair pathway 5, production of inflammatory cytokines 6 and inflammatory 
prostaglandins 7. 
However, there are several gastric carcinogenesis genes whose association with the 
evolution of GCPLs has not yet been evaluated. Among these, there are genes coding 
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against infection, and others with important functions in the gastrointestinal 
physiology. A significant association between genetic polymorphisms of these genes 
and the evolution of GCPLs would be an indication of the role of their proteins on GC 
development. Depending on the results obtained, it could also contribute to the 
characterization of biomarkers for the identification and surveillance of patients with 
precursor lesions at higher risk of progression to GC. In intermediate risk populations 
such as Spain, this approach might help to reducing advanced GC occurrence 8. 
The objectives of the present study were therefore to validate the genetic associations 
with the evolution of GCPLs identified in our previous study 4,and to assess the genetic 
association with other novel candidate genes, in an independent, long-term follow-up 
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Materials and Methods  
Patients and samples 
Patients and biological samples were obtained from a previously reported 
observational longitudinal study of GCPLs 9. Briefly, during 2012-2013, all patients with 
histological diagnoses of CAG, IM or dysplasia between 1995 and 2004 were identified 
from the Pathological Anatomy Department’s files of 9 public hospitals of Spain. 
Inclusion criteria were 25-69 years of age, absence of peptic ulcer, Barrett’s esophagus, 
GC, other cancer or gastric resection, and available clinical and demographic 
information. Patients following the inclusion criteria were invited to a new gastroscopy 
with gastric biopsy and saliva or blood collection for DNA extraction, and answered a 
clinical and lifestyle information questionnaire. All patients signed an informed consent 
to participate in the study, whose protocol was approved by the Ethical Committee of 
each hospital. The final sample size was 559 patients, followed for a mean of 12 years, 
with information on their GCPLs and available DNA. 
Histopathology 
As previously reported 9, for the recruitment biopsy each hospital followed their 
standard procedures at the time of the first gastric biopsy, although only patients with 
biopsies that fulfilled a minimum quality criteria (a paraffin block including at least 3 
fragments, each one of 1.5mm minimum size and in which both antrum and oxintic 
gastric mucosa were recognized) were selected and collected for histological 
evaluation. For the end of follow-up gastroscopy, five specimens were obtained 
according to the Sydney recommendations 10 (one from the incisura angularis, two 
from the antrum, and two from the corpus of the stomach). The gastric endoscopy was 
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standard clinical procedures of each department. When this study was performed, 
there were no established recommendations on the best endoscopic procedures 11; 
therefore, no image enhancement techniques were used to properly identify lesions. 
All biopsies (baseline and final), were formalin fixed and paraffin-embedded. Available 
sections of the baseline biopsy and those obtained from the final biopsy were used for 
histological diagnosis, following the usual procedures in each hospital. Diagnoses were 
made with one slide stained with hematoxylin and eosin (HE), although some centers 
also used Alcian blue- periodic acid Shiff (pH 2.5). The same pathologist from each 
hospital reviewed the initial and final biopsies following a common standard protocol 
for the diagnoses and classification of cases.  
Patients’ lesions were classified according to the most advanced lesion in the Correa’s 
cascade 2 diagnosed in any of the biopsy fragments collected at recruitment as well as 
at the end of the follow-up 9. The lesions were scored as follows:  1 = normal, 2 = non-
atrophic gastritis (NAG), 3 = non-metaplastic multifocal atrophic gastritis (CAG), 4 = 
complete intestinal metaplasia including predominant complete (CIM), 5 = incomplete 
IM including predominant incomplete (IIM), 6 = dysplasia (DYS) and 7 = gastric cancer 
(GC). We have used subtyping of IM to classify the risk, a method that is considered 
valid, simple, cheap and useful for clinical practice 12. The histological diagnosis at 
recruitment was: CAG, CIM, IIM and DYS. The classification at the end of follow-up 
was: normal mucosa, NAG, CAG, CIM, IIM, DYS and GC.  As in our previous study 4, 
based on the diagnosis at recruitment and at the end of follow-up, it was considered 
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regressed at least one point in the overall score (1 to 7). The lesions were considered 
to be stable if they maintained the same score.  
H. pylori infection and genotyping 
H. pylori status at recruitment was determined by cagA and vacA genotyping. DNA 
extraction from the FFPE block at recruitment was performed by phenol-chloroform 
method. After checking for the integrity of FFPE DNA by means of ACTB gene 
amplification, the ureA gene and the vacAs, vacAm and cagA virulence factor genes of 
H.pylori were genotyped by PCR amplification in a 7500Fast Real-Time PCR System 
(Applied Biosystems), using custom locked nucleic acids primers (LNA, Exiqon, 
Denmark) and SensiMixdU SYBR® Green Kit (Quantace Ltd, UK). The lengths of the 
amplified products were estimated in an Agilent 2100 Bioanalyzer using a DNA1000 lab 
chip (Agilent Technologies Inc., Palo Alto, CA, USA). Details on cagA and vacA 
genotyping are described in the online Supporting Methods. 
 Infection by H. pylori was considered positive if at least two PCR were positives among 
ureA, vacAs, vacAm and cagA. When only one or none of the PCR was positive, 
infection by H. pylori was considered negative.  
H. pylori status was also determined by Giemsa staining and from the medical records 
(rapid urease and urea breath tests) and interviews about previous H.pylori infection. 
All patients having at least one positive diagnostic in any of these sources of 
information were considered positive. 
Sample collection and DNA extraction for SNP genotyping 
At collection, between 1 to 5 ml of saliva were mixed with an equal volume (1:1) of a 
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DNA extraction for SNP genotyping was performed by phenol-chloroform method for 
saliva and FFPE samples, and by the salting-out method for blood samples. Only in a 
minority of cases (5%) DNA was obtained from FFPE gastric mucosa or from whole 
blood. DNA was dissolved in Tris-EDTA 1X and diluted to 50 ng/µl in dH2O for 
genotyping.  
Selection of candidate genes and SNPs 
We selected human candidate genes influencing gastric carcinogenesis from studies 
using mouse models of GC 13, as well as from the H.pylori infection pathway 14. After 
this gene selection, the SNP Genotype Data of European population (CEU) for each 
gene plus 5 and 3 Kb upstream and downstream respectively, was downloaded from 
the HapMap Genome Browser release #28 (Phases 1, 2 & 3 - merged genotypes & 
frequencies, dbSNP b126). Genotype data was analyzed with Haploview v.4.2 15, 
setting MAF≥0.05 and using the LD blocks definition of confidence intervals 16. tagSNPs 
were selected using the Tagger Aggressive option (2 and 3 marker haplotypes) with 
r2=0.8. Additionally, we also included SNPs associated with GC from GWAS studies17–20 
as well as SNPs associated with the evolution of GCPLs from a previous study of our 
group 4.  
Altogether, we selected 148 SNPs from 29 human genes: 10 human orthologues from 
mouse models of gastric cancer, 11 genes of the H. pylori pathways triggered by the 
infection, 6 genes previously associated with gastric cancer in GWAS, and 7 genes with 
SNPs previously associated with the evolution of GCPLs, 5 of which also belonged to 
other groups. Supporting Table 1 shows the analyzed genes and genotyping data of the 














Genotyping was performed with the MassArray iPlex-Gold technology (Sequenom) at 
the National Genotyping Center of Spain (CEGEN) in a customized assay design. To 
assess the genotyping error rate, a trio of Coriell samples and 5% of test samples 
duplicated at random were included for quality control. No genotyping assay could be 
designed for three tagSNPs of MAP3K14 and one of IL1B.   
Statistical Analysis  
Patients were categorized into groups of progression, regression and stables 
depending on whether the severity of their histological GCPLs increased, decreased or 
remained stable between recruitment and the end of follow-up. Chi2 test for 
contingency tables was performed to evaluate differences between the above 
mentioned groups in population characteristics (sex, age, NSAID consumption, family 
history of GC, smoking, H. pylori infection and histological diagnosis).  
A chi2 goodness of fit test was used to check if genotypes were in Hardy-Weinberg 
equilibrium (p>0.001) in all the samples. Association between the SNP genotypes and 
the evolution of the lesions was analyzed by multinomial logistic regression comparing 
genotypes in those lesions that progressed or regressed against those in the lesions 
that remained stable, as the reference group. This analysis was performed using the 
nnet package implemented in the R software21. Association was also analyzed by 
binomial logistic regression, comparing progression with stables and regression with 
stables. For this analysis the SNPassoc library of the R software was used. In all 
analyses ORs were calculated under codominant, dominant, recessive and log-additive 
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Test (LRT) was used to assess the significance of the association. Results were 
considered significant if p-value<0.05. The False Discovery Rate (FDR) test22  was 
applied to correct for multiple comparisons in both analyses. An association was 
considered significant if the p-value of the FDR test was p≤0.05. 
A sub-analysis of association according to the presence of H. pylori virulence factors 
was also carried out by multinomial logistic regression comparing: i) cagA+ (N=241) vs 
cagA- (N=119) and ii) High Virulence (HV) vacAs1m1-cagA+ (haplotype s1m1-1, N=164) 
vs Low-Intermediate Virulence (LIV, N=149), that includes all cagA-vacA haplotypes 
different from s1m1-1, among which there are 39 low virulence vacAs2m2-cagA-
strains. For some samples where it was not possible to obtain a reliable haplotype, this 
partial haplotypes were classified as ‘missing’ and excluded from analysis. This was 
performed because people infected with cagA+ and vacA s1/m1 strains are at 
increased risk of developing GCPLs and GC 23  as well as because virulence factors have 
been found associated with the progression of GCPLs 24. The Wald test was used to 
check for heterogeneity.  
All analyses were done using the same reference allele for each SNP, which was the 
commonest one in the general population (Supporting Table 1). 
Haplotype frequencies were inferred using the EM (expectation-maximization) 
algorithm implemented in haplo.stats package of R software 21. Associations between 
progression or regression and each haplotype with a frequency ≥0.01 were estimated 
by binomial logistic regression using the most frequent haplotype among the stable 















The available sample for statistical analyses was 141 SNP successfully genotyped in 559 
patients’ samples. Based on the evolution of the lesions the patients were grouped as 
stables (N=259, 46.3%), regression (N=204, 36.5%) or progression (N=96, 17.2%). Their 
main characteristics (sex, age, and family history of GC, smoking, NSAID consumption, 
H.pylori infection and histological diagnosis of the analyzed population at recruitment) 
are shown in Table 1. When the distribution of these variables in the evolution groups 
was compared, significant differences (p<0.0001, Table 1) were only observed for 
histological diagnosis at recruitment.  
All genotyping results are indicated in Supporting Table 1. Seven SNPs initially selected 
for genotyping [rs11079008 (GAST), rs6090575 (SRC), rs4072037 (MUC1), rs2236851 
and rs6688452 (RUNX3), rs28362491 (NFKB1), rs6890699 (CDX1)] were excluded from 
statistical analysis because they generated continuous or overlapping clusters. 
Genotype agreement in the Coriell samples was 100% and in the duplicated samples 
was of 99%. All SNPs were in Hardy-Weinberg Equilibrium (p>0.001).  
Table 2 reports all significant associations (p-value<0.05) between the analyzed SNPs 
and the evolution (progression or regression) of the GCPLs when compared to the 
stables group, in the multinomial logistic regression analysis. When a SNP was found 
significant under different inheritance models, the reported result is the one obtained 
under the most significant model.  
It can be observed that SNPs in CD14, CDH1, MAP3K14, MAPK3, MUC2, NFKB1, 
NFKBIA, NOD1, PTGS2, SRC and TFF2 were associated with the evolution of GCPLs in 
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TFF2 variants was weak (Table 2). When the ORs for progression or regression were 
analyzed it was observed that variants in CD14, NFKB1 and NFKBIA were associated 
with both progression and regression in the same direction. However, other genes 
were associated only with progression (MAPK3 and PTGS2) or with regression (MUC2 
and SRC). TFF2 rs1079380 showed a slightly significant association with the evolution 
of the lesions, with a positive effect on regression and an inverse effect on progression 
that did not reach statistical significance.  
After applying the FDR test to correct for multiple comparisons, the unique SNPs that 
remained significant were rs11167532, rs2569190 and rs1583005 in CD14, rs10902073 
in MUC2and rs1598861 and rs7674640 in NFKB1. Surprisingly, all these SNPs with the 
exception of MUC2 rs10902073 were associated in the same direction with both 
progression and regression of the lesions, although the effect was higher on 
progression. In the case of MUC2, as previously described 4, both SNPs (rs10902073 
and rs10794281) were inversely associated with regression, although only rs10902073 
passed the FDR test (Table 2).   
An additional binomial association analysis was also performed to compare 
progression vs stables, and regression vs stables (Supporting Table 2). CD14 SNPs 
rs11167352, rs2569190 and rs1583005, and NFKB1 rs1598861 and rs7674640 were 
also found to be associated with both progression and regression of the lesions in the 
same direction, although after adjustment for multiple comparisons, the CD14 SNPs 
remained significant only for the association with progression while NFKB1 rs1598861 
maintained significance only with regression; rs7674640 was significantly associated 
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rs10794281 were also inversely associated only with regression, although these 
associations did not reach significance after FDR (p=0.06 for MUC2 rs10902073, 
Supporting Table 2). This binomial analysis revealed some additional associations with 
variants in the IL1B, IL1RN, PTGES and TFF1 genes, but in all cases the associations 
were weak and none of them passed the FDR test.  
In general, the haplotype analysis (Table 3) confirmed the associations observed at 
single SNP level. Thus, the MUC2 haplotype containing the A and C alleles of 
rs10902073 and rs10794281, respectively, showed a significant inverse association 
with the regression of the GCPLs. The CD14 haplotypes GTGT and GCGC, both 
containing the more common G ‘risk’ alleles of rs11167532 and rs2569190, were 
positively associated with progression as well as with regression. Similarly, the NFKB1 
haplotypes GCAGAG and GCAGGA, both containing the G and A ‘risk’ alleles of 
rs980455 and rs1598861, respectively, were also positively associated with progression 
as well as with regression (Table 3). Haplotype analysis from the other genes was also 
in good agreement with the single SNP analysis (Table 2 and Supporting table 2), with 
the exception of the PTPN11 CAGGAGC haplotype which was inversely associated with 
regression when none of the SNPs were. 
In order to analyze the effect of the genetic variants according to the virulence of 
H.pylori strains, we repeated the analyses stratifying by cagA status (positive and 
negative) as well as by cagA and vacA haplotype, grouping into high virulence strains 
(HV, cagA+ and vacAs1m1) and low-intermediate ones (LIV, vacA no s1m1, 
independently of cagA status). The results obtained (Supporting Tables 3 and 4) 
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and a good general agreement between results stratified according to cagA 
presence/absence and those stratified according to cagA and vacA haplotypes (high or 
low virulence). Nevertheless, the heterogeneity analysis revealed that only a few of 
these SNPs had a significant differential effect according to H.pylori virulence 
















The identification and replication of human genetic variation statistically associated 
with the evolution of GCPLs may be relevant to reveal genes influencing gastric 
tumorigenesis. Only four association studies 4-7 have evaluated the genetic variability 
with respect to GCPLs evolution. In one of these studies performed by our group, 
MUC2 variants rs10902073 and rs10794281 were found inversely associated with 
regression of GCPLs 4, rs2569190 of CD14 and rs1079380 in TFF2 were inversely 
associated with progression and NFKB1 rs28362491, a SNP not analyzed in this study, 
was associated  with both progression and regression of the lesions (unpublished). In 
the present study we have evaluated the replicability of these and other associations, 
and have analyzed for the first time other genes not previously considered and having 
key roles in gastrointestinal physiology and in the interaction with H. pylori, influencing 
inflammation and, potentially, the evolution of GCPLs. Of all analyzed genes, two of 
the H.pylori pathway (NFKB1 and CD14) and one of the epithelial mucous barrier 
(MUC2) exhibited the most relevant associations. Although several other significant 
associations have been observed, most of them in genes of the H.pylori infection 
pathway, only variants in MUC2, CD14 and NFKB1 remained significant after 
adjustment for multiple comparisons. Furthermore, when the haplotype analyses were 
performed, the results obtained agreed with those of the single SNP analyses and 
confirmed the association of common haplotypes in these genes with the evolution of 
the lesions. When the analyses were stratified according to H.pylori virulence factors 
cagA and vacAs/m, none of the MUC2, CD14 and NFKB1 variants that were significant 
after the FRD test in the general analyses had a differential effect on the evolution of 
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findings from our group indicating that CD14 variation is associated with GC of the 
cardia, a cancer location not associated with H.pylori infection 14. Although in the same 
study NFKB1 variants showed a nominal significant association with distal GC, which is 
the cancer location associated with H.pylori infection 14, cagA and vacA have been 
shown to be dispensable for direct NF-kB activation 25. On the other hand, some SNPs 
in genes (particularly NOD1 and TFF1) not significant in the general analyses had a 
significant differential effect in the evolution of the lesions according to either cagA or 
cagA and vacA status, although none of the associations passed the FDR test, probably 
because the stratification of patients reduces sample size and statistical power.  
Additionally, the virulence could not be determined in 166 patients (29%), probably 
because H.pylori had already disappeared at recruitment. It is known that H.pylori does 
not colonize gastric areas with extensive atrophy or intestinal metaplasia 2, which were 
inclusion criteria for the study. 
Mucins are the major components of gastric mucus which protects gastric mucosa 
against bacterial infection, proteolytic enzymes and hydrochloric acid. They also limit 
the activation of inflammatory responses at the interface with the environment. Their 
over-expression, aberrant intracellular localization and changes in glycosylation 
pattern have been associated with various cancers26. MUC2 is a highly O-glycosylated 
secreted mucin expressed in both histological subtypes of intestinal metaplasia, but 
not in healthy stomach 2. MUC2 expression is increased in carcinomas of the 
gastrointestinal tract; however, Muc2-/- mice develop intestinal adenocarcinomas 27  
and it has been suggested that its overexpression in gastric carcinomas might reflect 
the origin of these tumors from intestinal metaplasia, rather than a role for this mucin 
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intestinal tract, attributed to protection of the intestinal epithelium against infection 
and inflammation, an oncogenic role of MUC2 overexpression has also been suggested 
as a result of a decreased activation of innate and adaptive immune responses 26. 
Therefore, it is biologically plausible that the genetic association of MUC2 variation 
with the evolution of GCPLs reflects changes in MUC2 expression in intestinal 
metaplasia or in its immunomodulatory role, although functional studies would be 
necessary to be conclusive. Although there is no information in the GTEx portal 
(https://gtexportal.org/home/) on MUC2 eQTLs influencing MUC2 expression in 
stomach, SNPs rs10902073and rs10794281 tag a strong LD block in the 5’-upstream 
region of the gene, suggesting that variation in this region may influence MUC2 
expression. It is also possible that the associated SNPs are in linkage disequilibrium 
with a functional variant in this gene. Other MUC2 variants significantly associated 
with the evolution of GCPLs in our previous study 4 have not reached significance in the 
present study but the association results obtained are in the same direction as in the 
previous study. Conflicting findings of this type could be attributed to differences in 
sample size, population structure and allele frequencies between the analyzed 
populations 28. 
CD14 is expressed by monocytes/macrophages and functions as a receptor for 
bacterial lipopolysaccharide and a mediator of the inflammatory response to H.pylori 
29. Although an inverse association with progression of CD14 rs2569190 had also been 
observed in our previous follow-up study of GCPLs 4, in that study the most common 
and reference allele was A instead of G. On the other hand, it is noteworthy that the 
same three SNPs associated with GCPLs evolution in this study had been previously 
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the rs2569190 variant has been shown to be associated with CD14 protein expression 
in monocytes 30, altogether being  in agreement with  its genetic association with the 
evolution of the GCPLs. 
NFKB1 (nuclear factor kappa-, subunit 1) is the other relevant gene associated with 
evolution of GCPLs. It encodes for a transcriptional factor that induces the expression 
of pro-inflammatory cytokines, chemokines and cell adhesion molecules to elicit an 
immune response against H.pylori infection. The continued expression of these 
cytokines due to the bacterial infection causes a chronic inflammation that leads to 
GCPLs that could progress into GC 31. Therefore, it is also biologically plausible that 
genetic variants in NFKB1, by modifying its expression or function, influence the 
progression of GCPLs.    
It is remarkable to observe that variation in CD14 and in NFKB1, as well as in other 
genes of the inflammatory response to H.pylori infection that did not reach 
significance after FDR (NFKB1A, MAPK3, NOD1), is associated in the same direction 
with both progression and regression of the GCPLs, suggesting a dual role of these 
genes in the evolution of the lesions. A similar result was also obtained in our previous 
study with NFKB1 rs28362491, which was significantly associated with both the 
progression [OR(95%CI)=1.55 (1.06-2.28)p=0.024] and the regression [OR(95%CI)=1.53 
(1.04-2.24)p=0.028] of the lesions (unpublished results). These apparently 
contradictory results, which exclude these genetic variants as biomarkers of the 
progression of the GCPLs, could be explained by the fact that these are SNPs in genes 
of mediators of the inmunoinflammatory process 32,33 and that inflammation has an 
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carcinogenesis 34-36.  Furthermore, this dual role will very much depend on the tumor 
microenvironment and the stage of the inflammatory reaction and tumorigenic 
process 34,36, which is unknown for our samples. For example, the TGFβ signaling 
pathway exerts tumor suppressor effects in normal cells and early tumors; however as 
these early tumors develop, the protective effects of TGFβ are lost and its activation 
changes to promote cancer progression 35. The expression of pro-inflammatory 
cytokines protects gastric tissue by recruitment of effector cells during H. pylori acute 
inflammation. However, when this process becomes chronic, the same pro-
inflammatory cytokines produce excessive cell proliferation and free radical 
production, conditioning tumor transformation, reminiscent of the effects of acute and 
chronic inflammation 36,37.  Such a dual role on both progression and regression of the 
lesions has not previously been reported by other genetic association studies. 
Nevertheless, it is to note that these previous studies were on other pathway genes 
such as DNA repair genes 5, or they only reported the association with progression 6,7. 
The main strengths of our study are that we followed-up the evolution of GCPLs of a 
relatively large cohort of patients from Spain for a mean of 12 years. Besides, it has a 
larger sample size and we have analyzed a larger number of candidate genes than 
previous studies 4-7. In contrast to the majority of studies that analyze either the host 
or the bacterial genetic factors, the present study explores both of them in the same 
patient allowing for stratified analyses according to H.pylori virulence factors. In 
addition, the H.pylori status and the virulence factors were determined in the 
recruitment biopsy sample. This is relevant because some biopsy specimens harbor 
multiple strains with different virulence that may be selectively lost during 
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genetic association study with two different outcomes, the failure in genotyping some 
tagSNPs, which reduces the coverage of their gene variability, as well as a possible bias 
in the classification of the gastric lesions or insufficient gastric mucosa sampling. 
Regarding sample size, this is something difficult to increase given the study and 
patients’ recruitment characteristics 9; nevertheless, although a greater sample size 
could have increased the power of our study to identify significant associations, there 
are reasons to believe that the significance of the reported associations is real: 1) they 
remain significant after adjustment for multiple comparisons, 2) they validate some 
previous findings and 3) they have biological plausibility. Regarding possible bias,  in 
fact there is debate on whether the progression or regression of GCPLs observed from 
gastric biopsies taken at different time points are real or may be biased by mucosa 
sampling 2. Recent clinical management guidelines for H.pylori infection agreed in that 
intestinal metaplasia cannot be reversed by bacterial eradication, although its 
progression is arrested in a subset of patients 38,39. Nevertheless, recent studies 
indicate that IM can regress after H.pylori eradication treatment 40,41 and another 
study on the molecular determinants of progression of gastric cancer identifies 
patterns associated with IM regression 42.   
Recent findings indicate that  H. pylori eradication treatment has an effect on the 
progression of the lesions 40,41. Analysis of a subset of patients (n=287) of our study 
which were positive for H. pylori infection and had information on eradication 
treatment, did not reveal significant differences on regression or progression of the 
lesions (Chi2 test) according to treatment.  It is to mention that since our study was not 
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infection at follow-up was not evaluated from H. pylori genotyping but from medical 
records and patients’ questionnaires.   
In conclusion, our study confirms previous results according to which genetic 
variability in MUC2 is associated with the evolution of GCPLs and identifies novel 
significant associations with variants in NFKB1 and CD14, two genes of 
the H.pylori pathway whose association with the evolution of GCPLs has not been 
previously reported. Although these associations have a biological plausibility, they 
need validation in larger and independent populations. Moreover, since a tagSNP 
strategy was used to optimize the coverage of gene variability,   linkage disequilibrium 
analysis, as well as expression and functional studies, will be required to identify the 
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Table 1. Characteristics of the analysed population at recruitment. 














N % N % N % N %  
Sex          
   Men 137 52.9 108 52.9 57 59.4 302 54.0 0.51 
   Women 122 47.1 96 47.1 39 40.6 257 46.0  
Age          
    ≤50 years 103 39.8 93 45.6 32 33.3 228 40.8 0.12 
    >50 years 156 60.2 111 54.4 64 66.7 331 59.2  
NSAID consumption          
    YES 136 52.5   95 46.6 43 44.8 274 49.0 0.58 
    NO 122 47.1 102 50 46 47.9 270 48.3  
    Missing      1   0.4     7   3.4   7   7.3   15   2.7  
Family history of GC          
    YES   40 15.4   18   8.8 16 16.7   74 13.2 0.08 
    NO 215 83.0 174 85.3 74 77.1 463 82.8  
    Missing     4   1.6   12   5.9   6   6.2   22   3.9  
Smoking          
    Current or ex-smoker 149 57.5 112 54.9 53 55.2 314 56.2 0.88 
    Never smoker 109 42.1   88 43.1 37 38.5 234 41.9  
    Missing     1   0.4     4   2.0   6   6.3   11   1.9  
H. pylori infection          
    YES 172 66.4 134 65.7 55 57.3 361 64.6 0.69 
    NO   78 30.1   58 28.4 30 31.2 166 29.7 
    Missing     9   3.5   12   5.9 11 11.5   32   5.7  
    cagA+ 117 68.0 89 66.4 35 63.6 241 66.7  
    cagA-   54 31.4 45 33.6 20 36.4 119 33.0 0.79 
    Missing     1   0.6   0   0   0   0      1   0.3  
    cagA+vacAs1m1-1   83 48.3 53 39.6 28 51.0 164 45.4  
    cagA-vacA no s1m1-1    64 37.2 66 49.2 19 34.5 149 41.3 0.09 
    Missing   25 14.5 15 11.2   8 14.5   48 13.3  
Histological Diagnosis 
e          
     CAG   52 20.1 54 26.5 35 36.5 141 25.2 < 0.0001 
     CIM 116 44.8 56 27.4 43 44.8 215 38.5 
     IIM   83 32.0 83 40.7 18 18.7 184 32.9 
     DISP     8   3.1 11   5.4   0   0   19   3.4 
a, b, c
 Evolution groups of the gastric cancer precursor lesions (GCPLs), as defined in Materials and 
Methods section. Percentages are indicated with respect to each evolution group except for H. pylori 
cagA and vacA virulence groups, where the percentages are calculated with respect to the total of H. 




 test of comparison.  NSAID: Non-steroidal anti-inflammatory drug.   
e
CAG: 















Table 2. OR (95% CI) of SNPs associated with progression and regression of GCPLs after 
multinomial logistic regression analysis. 
Gene SNP a Alleles b LRT p-value FDR q-value OR (CI 95%) 
Progression 

















0.456 1.3 (0.8-2.1)  1.6 (1.1-2.4)  Dominant 
CD14 
 
rs2569190  G/A 0.0003 0.017 
 
0.5 (0.4-0.8) 0.7 (0.5-0.9) Log-additive 
CD14 
 
rs5744455 C/T 0.014 0.219 
 





C/T 0.0004 0.017 
 














1.3 (0.7-2.4)  0.5 (0.3-1.0)  Log-additive 




2.1 (1.2-3.9)  1.5 (1.0-2.3) Dominant 
MUC2 
 




0.9 (0.7-1.3) 0.6 (0.5-0.8)  Log-additive 
MUC2 
 
rs10794281 T/C 0.046 0.373 
 





















1.7 (1.0-2.8)  1.6 (1.1-2.4)  Dominant 
NFKB1 rs7674640  
 
T/C 0.000037 0.003 
 
0.3 (0.2-0.6) 0.5 (0.3-0.7) Recessive 











1.5 (0.9-2.6)  1.5 (0.9-2.3)  Codominant 
PTGS2 
 




0.6 (0.4-0.9) 0.8 (0.6-1.05) Log-additive 
PTGS2 
 




















0.8 (0.5-1.1)  1.2 (0.9-1.6)  Log-additive 
a
SNPs marked in bold are significant after the FDR test. 
b
 Common allele (reference)/Variant allele. 
c
When the same SNP 
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Table 3. Haplotypes significantly associated with the evolution of GCPLs.  






























ATAC 0.44   1 
(Referen
ce) 














 GCGC 0.27 1.7 (1.1-
2.6) 








AA  0.39 1 
(Referen
ce) 




  AG 0.27    1.1 
(0.7-1.8) 











TTCT 0.47 1 
(Referen
ce) 




  CTCC 0.32 1.0 (0.7-
1.5) 







CT  0.56 1 
(Referen
ce) 




 AC 0.38 0.9 (0.7-
1.3) 
NS 0.33 0.6 (0.5-
0.9) 
0.00





























0.06 2.  (1.1-
4.1 ) 







GA 0.70  
(Referen
ce) 




  AG 0.15 0.6 (0.3-
1.0) 









AAT  0.48 1 
(Referen
ce) 




  GAC 0.10 1.0 (0.6-
1.8) 











TTCGAT 0.21 1 
(Referen
ce) 






































0.19 0.9 (0.6 -
1.4) 










AGTC 0.38 1 
(Referen
ce) 




  AACC 0.11 2.0 (1.2-
3.5) 
0.01 0.11 1.2 (0.8-
1.8)   
NS 
a
The underlined alleles indicate which SNPs are associated with evolution of GCPLs. 
b, c
Odd ratios (CI 95%) and 
p-values of haplotypes significantly associated with the evolution of GCPLs. ORs were calculated according to 
the binomial logistic regression log-additive model with the reference haplotype being the commonest one. NS 
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